-
公开(公告)号：EP4285938A1
公开(公告)日：2023-12-06
申请号：EP22746295.9
申请日：2022-01-28
Inventor： CHO, Kwang Hyun , CHOI, Sea Rom , HWANG, Chae Young , LEE, Jong Hoon
IPC: A61K48/00 , A61K31/7105 , A61K38/15 , A61K31/138 , A61K45/06 , A61P35/00 , A23L33/13 , A23L33/18
Abstract: The present invention relates to a pharmaceutical composition for treating or preventing malignant breast cancer and, more particularly, to a composition for transdifferentiation of ER-negative breast cancer to luminal breast cancer, comprising an HDAC1/2 inhibitor and a BCL11A inhibitor as active ingredients, and use of the composition. According to the present invention, when target genes of the present invention are inhibited, BLT is induced so that basal-like or triplet-negative breast cancer is transdifferentiated to luminal A subtype breast cancer which is responsive to anticancer therapy, that is, being curable by hormone therapy. Accordingly, an effective and novel drug treatment that has not been conventionally attempted may be provided, thereby not only increasing the survival rate of patients through targeted therapy by realizing personalized medicine, but also contributing to an improvement in the quality of life that results from unnecessary anticancer drug therapy.
-
Patent Agency Ranking2.发明公开
公开(公告)号：EP4498085A1
公开(公告)日：2025-01-29
申请号：EP23775311.6
申请日：2023-03-22
Inventor： CHO, Kwang Hyun , LEE, Jung Eun , GONG, Jeong Ryeol
IPC: G01N33/50
Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer, comprising a DEAD-box helicase 54 (DDX54) inhibitor and a cancer immunotherapy agent, and to a combination therapy of cancer immunotherapy. The DDX54 inhibitor according to the present invention can enhance the efficacy of cancer immunotherapy when used in combination with a cancer immunotherapy agent, and the composition containing the DDX54 inhibitor and a cancer immunotherapy agent inhibits proliferation of cancer, which is a key characteristic thereof, and simultaneously inhibits a signal transduction pathway known as an immune evasion mechanism, and thus may be provided for the prevention or treatment of cancer.
-
公开(公告)号：EP4497836A1
公开(公告)日：2025-01-29
申请号：EP23775342.1
申请日：2023-03-23
Inventor： CHO, Kwang Hyun , GONG, Jeong Ryeol , LEE, Chun Kyung , KIM, Hoon Min , KIM, Ju Hee
IPC: C12Q1/6886 , C12N5/09 , C12N15/85 , A61P35/00
Abstract: The present invention relates to a method for constructing a gene network through a single-cell transcriptome and a method for discovering key genes in differentiation using same, and a composition for the prevention, alleviation, or treatment of colon cancer using the target discovered through the method. The method for constructing a gene network of key genes according to the present invention employs single-cell transcriptome data and thus can be applied to all single-cell transcriptome data. The combination of MYB/HDAC2/FOXA2 discovered upon application to colon cells can serve as a cancer treatment target that promotes the differentiation of colon cancer cells to revert same into differentiated normal cells.
-
4.发明公开
公开(公告)号：EP4491745A1
公开(公告)日：2025-01-15
申请号：EP23767176.3
申请日：2023-03-08
Inventor： CHO, Kwang Hyun , GONG, Jeong Ryeol , KIM, Ju Hee
IPC: C12Q1/6886 , C12N9/10
Abstract: The present invention relates to a composition comprising a SETMAR inhibitor for preventing or treating cancer. It has been identified that if SETMAR is inhibited in cancer cells, carcinogenesis reversion, which is the differentiation of cancer cells into normal cells, is successfully achieved, and thus, unlike conventional anticancer agents that simply induce cancer cell death, the present invention can be effectively used as a treatment method excluding the side effect of normal cell death that can occur during anticancer treatment, and converting cancer cells into normal cells.
-
公开(公告)号：EP4455664A1
公开(公告)日：2024-10-30
申请号：EP22912037.3
申请日：2022-12-23
Inventor： CHO, Kwang Hyun , LEE, Hye Min , GONG, Jeong Ryeol
Abstract: The present invention relates to a composition comprising a TAF10 inhibitor for preventing or treating colorectal cancer. The inhibition of TAF10 was found to lead to suppressing the growth and proliferation of colorectal cancer cells, reducing vascularization, and inhibiting the WNT signaling pathway, and increase the survival rate of patients as analyzed with a large-scale cancer database. In particular, reversal of the cancerization process, which is the differentiation of colorectal cancer cells into normal cells, was confirmed. Unlike conventional anticancer agents that simply induce the death of cancer cells, the present invention can thus be advantageously utilized as a treatment method for converting colorectal cancer cells into normal cells while excluding side effects of normal cell death that may occur during anticancer treatment.
-
公开(公告)号：EP4272739A1
公开(公告)日：2023-11-08
申请号：EP21915823.5
申请日：2021-12-29
Inventor： CHO, Kwang Hyun , KIM, Nam Hee , HWANG, Chae Young , KIM, Tae Young
IPC: A61K31/496 , A61K45/06 , A61P35/00 , A61P35/04
Abstract: The present invention relates to a composition for inhibiting metastasis and enhancing anticancer drug sensitiviy, the composition removing, from cancer cells, stem cell properties and heterogeneity acquired by epithelial-to-mesenchymal transition (EMT), thereby being capable of inducing the cancer cells into a phenotype which has regained responsiveness to a chemotherapeutic agent. A combination of a p53 activator, a SMAD4 inhibitor and an ERK inhibitor of the present invention enables a mesenchymal cell phenotype to return to an epithelial cell phenotype, and also enables the ability of cancer cells to metastasize to be inhibited by overcoming the high plasticity and drug resistance of the cancer cells, and thus may be widely used in the field of cancer treatment.
-
-
-
-
-
Search Results
6
records
(took 0.013 seconds)
